Table 4. Effect of miltefosine lipid nanocapsule formulations (MFS-LNCs) on hepatic granulomas size in μm as compared with control groups.
F* = 110.924 (p<0.001).
| Animal group / Formulation code | ||||||||
|---|---|---|---|---|---|---|---|---|
| Granuloma size, μm | Infected untreated control | MFS-sol control | Group I | Group II | Group III | Group IV | Group V | Group VI |
| MFS-LNC | MFS-LNC -CTAB | MFS-LNC -CS | MFS-LNC -DCP- | MFS-LNC- -OA | MFS-LNC -OA-CTAB | |||
| Min. | 285.0 | 280.0 | 232.0 | 206.0 | 214.0 | 245.0 | 190.0 | 235.0 |
| Max. | 325.0 | 325.0 | 240.0 | 215.0 | 222.0 | 260.0 | 220.0 | 245.0 |
| Mean | 305.94 | 299.64 | 236.0 a b | 210.0 a b c | 218.17 a b c | 253.50 a b c d e | 205.0 a b c e f | 240.67 a b d e f g |
| SD | 13.49 | 15.84 | 2.65 | 3.16 | 2.71 | 5.43 | 11.90 | 4.41 |
| Median | 303.75 | 300.0 | 236.0 | 209.50 | 218.0 | 254.0 | 210.0 | 241.50 |
| % R 1 | 2.06 | 22.86 | 31.36 | 28.69 | 17.14 | 32.99 | 21.33 | |
| % R 2 | 21.24 | 29.92 | 27.19 | 15.40 | 31.58 | 19.68 | ||
* F test (ANOVA), % R1: % reduction in each of the study groups relative to infected control %R2: % reduction in each of the study groups relative to miltefosine solution control
a: significant with infected untreated control
b: significant with MFS solution control
c: significant with group I
d: significant with group II
e: significant with group III
f: significant with group IV
g: significant with group V